adult somatic tissues have proven difficult to expand in vitro, largely because of the complexity of recreating appropriate environmental signals in culture. We have overcome this problem recently and developed culture conditions for adult stem cells that allow the long-term expansion of adult primary tissues from small intestine, stomach, liver and pancreas into self-assembling 3D structures that we have termed 'organoids' . We provide a detailed protocol that describes how to grow adult mouse and human liver and pancreas organoids, from cell isolation and long-term expansion to genetic manipulation in vitro. liver and pancreas cells grow in a gel-based extracellular matrix (ecM) and a defined medium. the cells can self-organize into organoids that self-renew in vitro while retaining their tissue-of-origin commitment, genetic stability and potential to differentiate into functional cells in vitro (hepatocytes) and in vivo (hepatocytes and endocrine cells). Genetic modification of these organoids opens up avenues for the manipulation of adult stem cells in vitro, which could facilitate the study of human biology and allow gene correction for regenerative medicine purposes. the complete protocol takes 1-4 weeks to generate self-renewing 3D organoids and to perform genetic manipulation experiments. personnel with basic scientific training can conduct this protocol.
IntroDuctIon
Adult somatic tissue-resident stem cells are gaining much attention for their intrinsic ability to self-renew and differentiate into cell types present in adult tissues while retaining their genetic integrity and commitment to their tissue of origin 1 . The recent development of 3D cell culture conditions for adult organs has allowed the in vitro expansion of primary tissues from healthy adult mouse and human tissue, as well as from tissue affected by disease (patientderived tissue). In parallel, the development of human embryonic stem cell (ESC) and induced plurpotent stem cell (iPSC)-derived cultures that faithfully recapitulate the differentiation of ectoderm (e.g., retina and brain) 2, 3 and endoderm derivatives (stomach, small intestine, liver, lung or thyroid) 4, 5 has opened up avenues to study human development in vitro in an unprecedented manner.
In our previous studies, we developed a 3D culture system that allows the long-term expansion of small intestine 6 and stomach epithelial stem cells in organoid cultures 7 . Here we describe recently established protocols for the long-term expansion and genetic manipulation of adult liver and pancreas cells in 3D organoid cultures from mouse and human models. We also explain the utility of these organoid cultures in disease modeling [8] [9] [10] [11] [12] [13] .
Development of the protocol for organoid culture from liver and pancreas cells
The liver and pancreas develop from a common population of endodermal progenitors (reviewed in Zaret et al. 14 ) . Although the two organs share several aspects of their morphogenesis and development, they give rise to very distinct functional organs with very different regenerative capacities 14 . The liver is mainly formed of two types of epithelial cells: the hepatocytes and biliary epithelial cells (also known as cholangiocytes), which, together with several nonepithelial cell types (stellate cells, stromal cells, Kupffer cells and endothelial cells), generate the basic functional structure termed the hepatic lobule 15 . The pancreas is formed of two functionally distinct compartments: the exocrine compartment (comprising duct and acinar cells) and the endocrine compartment (composed of the islets of Langerhans). The genes and molecular pathways regulating the embryonic development of these two organs are evolutionarily conserved among all vertebrates studied. These include the FGF, HGF, Wnt, BMP, RA and TGFβ pathways that promote progenitor proliferation, migration and survival 14, [16] [17] [18] . Despite our knowledge of the signaling pathways involved during liver and pancreas development, in vitro expansion of adult pancreas or liver cells has remained a challenge. It was previously shown that primary liver cells could be maintained in culture in the presence of EGF, HGF and the corticoid dexamethasone 19 . However, these conditions did not allow the long-term expansion of liver progenitors. Similarly, mouse embryonic pancreas cultures that were able to differentiate into endocrine and exocrine lineages in vitro had been obtained from embryonic progenitor pools 20 or hESCs 21, 22 . However, these systems do not allow the long-term expansion of pancreas cells in vitro.
The knowledge acquired from developmental studies, combined with our own expertise in stem cell cultures from adult small intestine 6 and stomach 7 , allowed us to define, for the first time, culture conditions for the expansion and differentiation of mouse and human adult primary liver 8, 9 and pancreas 10, 11 tissue. Thus, by providing an ECM environment together with a combination of growth factors that are essential during liver spontaneously. To differentiate the proliferative cells along the hepatocyte lineage, we defined a differentiation medium. We found that blockade of ductal fate by Notch inhibition, a potent inducer of ductal morphogenesis 26 , in combination with the removal of Rspo1 and addition of dexamethasone and BMP facilitated the differentiation of the organoids to a hepatocyte fate, for both mice and humans ( Fig. 3a-c) 8, 9 . Shifting the cultures to this differentiation medium not only upregulated the expression of classic hepatocyte markers (cytochromes, albumin or α-1-antitrypsin (A1AT)) but endowed the cells with functional hepatocyte characteristics-such as albumin production, cytochrome activity or bile acid production-in vitro. Of note, when these hepatocyte-like cells were transplanted into a mouse model of tyrosinemia type I liver disease (FAH −/− mouse model) 8 or into an immunodeficient liver injury model with CCl 4 /retrorsine 9 , the organoid cells engrafted into the liver tissue, generating clusters of functional hepatocytes in vivo. Step 1A(i-x)
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Figure 1 | Schematic representation of organoid isolation, culture and characterization. The relevant steps of the protocol for each section are highlighted in red. Ducts or single cells can be isolated from human or mouse liver or pancreas (upper steps) and cultured to form 3D organoids (representative bright-field images of each species and tissue type shown 5-7 d after passaging). After expansion, organoids can be characterized using standard molecular biology techniques (bottom right steps) or they can be frozen for storage (bottom steps). Scale bars, 200 µm. UK NHS REC and Home Office permissions were obtained for the use of human and mouse samples, respectively.
The pancreas organoids are entirely composed of ductal (Sox9 + , Krt19 + ) cells that express the embryonic progenitor marker Pdx1 (ref. 27 ). To expand pancreas ductal cells, we used a protocol similar to that used for liver organoids. Thus, adult pancreas organoid cultures will expand in the long term in the presence of EGF, Rspo1, FGF10 and Noggin 10 . So far, the direct differentiation of these cells along endocrine lineages in vitro has proven unsuccessful. However, when adult pancreas organoid cells were mixed with embryonic E13 mouse pancreas cells and immediately transplanted into the kidney capsule of immunocompromised mice, the adult-derived organoid cells readily differentiated into fully mature, monohormonal (insulin-, glucagon-or somatostatin-positive) cells in vivo 10 . Using similar culture conditions, human pancreas duct cells can be expanded in vitro for 4-5 months 11 . However, their endocrine differentiation potential has not been assessed yet.
Genetic manipulation in organoid cultures. Genetic manipulation has been of crucial importance in understanding the biological function of numerous genes, and it has provided knowledge of how mutations in certain genes are the cause of diseases such as cancer and obesity [28] [29] [30] [31] . We have recently shown that gene transfer to organoids is feasible and that it allows the study of gene function, as well as gene targeting in vitro in 3D cultures 32 . For example, we successfully investigated the function of RNF43, a novel E3 ubiquitin ligase, by retroviral overexpression in organoid cultures, and so we defined it as a negative regulator of the Wnt pathway 33 . Similarly, CRISPR gene targeting allowed us to perform gene correction of the cystic fibrosis transmembrane conductor receptor in intestinal organoids derived from cystic fibrosis patients 13 . These examples demonstrate how retroviral gene overexpression and CRISPR/Cas-mediated gene editing can be used for the study of gene function, as well as for the potential application of autologous cell therapy.
Here we describe in detail two methods for gene transfer to liver and pancreas organoid cultures: first, retroviral transduction 12 , which allows stable integration of the gene of interest into the genome, and second, liposomal transfection, which allows transient transfection 13 . Collectively, these protocols will allow gene function analysis in murine and human organoid cultures by gene overexpression, knockdown or transient transfection. First, organoids are trypsinized to single cells. After dissociation, retroviral transduction efficiency is further enhanced by the addition of polybrene to the culture medium, which enhances virus adsorption to target cell membranes 34 . For transfection, genes are delivered using a liposomal agent (Lipofectamine 2000). The single cells are mixed with either virus or liposomal transduction or transfection mixture, and then spin-inoculated. We have found that spin inoculation is not essential; however, it increases the transduction or transfection efficiency substantially. After spin inoculation, single cells are incubated in the transduction or transfection mixture. Organoids are amenable to transduction by retroviruses, lentiviruses and adenoviruses 12, 35, 36 .
Future applications and potential limitations
Organoid cultures derived from adult liver and pancreas tissues can be very useful for studying human liver and pancreas biology in a primary, nontransformed, physiologically relevant system. The parallel development of genetic engineering tools to manipulate mammalian genomes has opened up the possibility of genetic modification of stem cells in vitro, which, when combined with 3D culture systems, might facilitate gene correction for regenerative medicine purposes.
As a general tool for the study of all kinds of disease, the culture of tissue biopsies from patients enables the study of the molecular mechanisms driving pathologies while at the same time providing a platform for gene editing for true autologous cell therapy. As an example, we have recently demonstrated that liver organoids derived from patients with A1AT deficiency or Allagile syndrome, who harbor germline mutations in the A1AT and Notch pathways, respectively, can partially mimic the phenotype of the patients in vitro 9 . In fact, A1AT organoids develop A1AT precipitates in the organoid cells that are similar to those seen in the liver cells from patients 9 . In addition, pancreas cancer organoid cultures have been used to model primary cancer tissue in vitro 11 . The ease of genetic manipulation using either retroviruses or CRISPR/Cas endonuclease may enable a better understanding of gene function in both pancreas and liver, and may accelerate advancements in the field of personalized medicine for pancreas and liver diseases. Bright-field images of the isolation and growth of organoids from mouse liver (a) and pancreas (b) using whole ducts (upper panels) and single cells (lower panels). For both tissues, ducts increase their lumen volume after 2 d in culture, and single cells will form full organoids after 6-7 d in culture. Organoids can then be expanded in the long term (after-splitting pictures were taken 3 months after isolation). Scale bars, 100 µm for the ducts (days 0 and 2), 25 µm for the single cells (days 0, 6 and 7) and 500 µm for organoids after splitting. Home Office permission was obtained for the use of mouse samples.
A current limitation of this culture system is that it is suitable only for the expansion of the adult epithelial compartment of the tissue. By contrast, human gastric organoids derived from hESCs 5 or liver buds derived from hiPSCs cocultured with mesenchymal and endothelial cells 37 have demonstrated the formation of gastric organoids and liver buds containing both mesenchymal and epithelial cells. Although these systems do allow the detailed study of tissue development and epithelial-mesenchymal interactions during organogenesis and tissue growth, they do not allow the long-term, exponential expansion of the tissue in vitro.
Overall, long-term, adult stem-cell-based organoid cultures represent an emerging field for culturing primary normal and diseased tissue in vitro. Combined with the tools for genome engineering, this 3D organoid culture holds great promise for the study of human liver and pancreas biology, as well as of the molecular mechanisms underlying disease establishment and progression.
Experimental design
In this detailed protocol, we describe recently established protocols for the long-term expansion and genetic manipulation of adult liver and pancreas organoid cultures. In this section, we discuss the experimental aspects that need to be considered before adapting the protocol for culturing and/or genetically manipulating liver and/or pancreas organoids to each experimentally distinct scenario.
Isolation of ductal cells. To isolate duct cells from mouse liver tissue, two alternative procedures can be used, depending on the requirement and possibility of perfusing the liver. Perfusing the liver is an option for mouse tissue, specifically when large populations of cells are to be isolated by FACS before growing them into organoid cultures. A suitable protocol for liver perfusion is beyond the scope of this procedure, but an example would be Klaunig et al. 38 . When liver perfusion cannot be performed-e.g. in the case of small biopsies of human tissue, or when there is no need to isolate large quantities of ductal cells-then the tissue will be processed to enrich for ductal structures. In the latter scenario, it is still possible to further digest ductal structures into a single-cell suspension if sorting of cells is needed.
When little starting material is available (e.g., in the case of biopsies) or when the rapid establishment of either mouse or human organoid lines is the primary aim, isolated ductal fragments from both pancreas and liver hand-picked from the bulk preparation (described in detail in PROCEDURE Step 1A(ix)) are sufficient to create a robust line in a rapid manner. Although this approach will only enrich ductal cells from the isolation rather than providing a pure population, we have found that contaminating (nonductal) cell types have been outcompeted and virtually eliminated from the culture after two passages. If the purification of ductal cells is required before the establishment of the line, then it will be necessary to use FACS. The ductal marker EpCAM could be used to isolate a purely ductal cell population 8, 10 . It is important to be aware that growth from single cells is less rapid than that from hand-picked ducts.
Establishment of organoid lines. The culture of long-term expandable liver and pancreas organoids allows the establishment of organoid lines to investigate aspects of liver and pancreas biology in vitro. Several characteristics can be considered when culturing organoids, such as colony formation efficiency (number of organoids formed), organoid size, cell proliferation rate, organoid morphology and gene expression [8] [9] [10] [11] . If human material is to be used, then either genetic manipulation or acquisition of samples from patients of interest will be necessary. When you are deriving lines from patients, ensure that appropriate ethics approval from relevant institutional and national bodies has been gained. Optimally, tissue pieces of at least 1 cm 3 would be used as the starting material. However, we have succeeded in isolating organoids even from fine-needle aspirates. Because of the nature of the material, the time that the biopsy sample has been outside of the body and its conservation are of critical importance. Tissues should always be transported in cold medium (4 °C). Consequently, we have found the variability in isolation efficiency to be greater in human than in mouse organoid lines. However, once cultures are established, the maintenance and expansion potential of the cultures is robust and reproducible.
Differentiation of liver organoids. The differentiation of mouse or human liver organoids into hepatocytes can be achieved in a robust manner using in vitro culture conditions 8, 9 , which we have provided here as part of the protocol. When cultured using the expansion medium, the cells mainly exhibit a ductal phenotype, and acquisition of hepatocyte fate is seen only in cultures in differentiation medium. The level of maturity of the differentiated cells can be examined by using gene expression and immunostaining analyses (typical markers: albumin, HNF4α, ZO-1 and Cyp3A). When planning experiments that involve the differentiation of liver organoids to hepatocytes, consideration should be given to controls, which are cultured in expansion medium for the same length of time and from the same starting material. This will identify either the starting material or the differentiation protocol as the area for optimization in the event of problems.
Although the differentiation of mouse pancreas organoids into endocrine cell types has been achieved 10 , the protocol requires specialized technical knowledge, including that of engraftment into the kidney capsule of a live animal. The differentiation capacity of human pancreas organoids has not been reported. For these reasons, we describe here only the differentiation of liver organoids and not pancreas organoids.
Histological analysis.
For best results, the fixation method will require optimization based on the application, antibody and antigen. The most widely used fixative is paraformaldehyde (4% (wt/vol) PFA), which shows broad specificity. Acetone fixation precipitates large protein molecules and is good for cytological preservation, but it might result in unwanted side effects because of cell permeabilization. We have found that for analyses centered on the detection of antibody signal, whole-mount staining is the better method. However, paraffin sectioning followed by histological staining is the preferred method when delineation of cellular morphology is required.
Genetic manipulation.
As genetic manipulation of the organoids requires dissociation into single cells, it is highly recommended to optimize the starting density and trypsinization time of the organoids to give optimal cell viability. When genetically manipulating liver or pancreas organoids, a highly recommended aspect to consider before the genetic manipulation is the use of a transduction or transfection control virus or plasmid that allows quick evaluation of the transduction/transfection efficiency (e.g., a GFP-expressing plasmid). This holds true for the transfection of Platinum-E (Plat-E) cells too, as to ensure a high virus titer the transfection efficiency of Plat-E cells should be 80%. Additional controls that should be included are mock-transduced or -transfected organoids that are treated with the selection agent during the selection procedure. The following retroviral vectors from Addgene allow transduction efficiency to be evaluated based on the expression of the red fluorescence protein dsRed: pMSCV-loxp-dsRed-loxp-eGFP-Puro-WPRE (32702), pMSCVloxp-dsRed-loxp-3×HA-Puro-WPRE (32703) and pMSCV-FLIPpuro-dsRed-GFP-miRNA (32704). In addition, the 3×HA epitope can be used to confirm gene overexpression (e.g., by western blotting). On the other hand, when performing gene knockdown, before organoid transduction, it is advised to validate the corresponding siRNA knockdown efficiency using standard transfection in appropriate cell lines (e.g., HEK293T cells) 12 .
MaterIals

REAGENTS
Male or female mice from any genetic background and aged from 6 weeks to 1.5 years can be used ! cautIon Experiments that involve rodents must be conducted in compliance with all relevant institutional and governmental regulations. We adhere to UK Home Office legislation and guidelines relating to the Animals (Scientific Procedures) Act 1986. Human liver/pancreas samples ! cautIon Consult ethics review board regulations and obtain informed consent from all subjects before collecting and processing human tissues. additional reagent setup Wnt3a-conditioned growth medium. Wnt3a-conditioned growth medium is DMEM supplemented with 10% FBS, 1% penicillin/streptomycin and 300 µg/ml Zeocin. Store the medium at 4 °C for up to 1 week.
Wnt3a-conditioned harvest medium. Wnt3a-conditioned harvest medium is DMEM supplemented with 10% FBS and 1% penicillin/streptomycin. Store the medium at 4 °C for up to 1 month.
Rspo1-conditioned growth medium. Rspo1-conditioned growth medium is DMEM supplemented with 10% FBS and 150 µg/ml Zeocin. Store it at 4 °C for up to 1 week.
Rspo1-conditioned harvest medium. Rspo1-conditioned harvest medium is Advanced DMEM/F-12 supplemented with 1% penicillin/streptomycin, 1% GlutaMAX and HEPES 10 mM. Store it at 4 °C for up to 1 month. procedure 1. Follow option A to make Wnt3a-conditioned medium or option B to make Rspo1-conditioned medium. Incubate the cells in this medium for 1 week. (iv) Remove the medium into 50-ml tubes. Centrifuge the mixture at 500g for 5 min at 8 °C to remove cells. (v) Filter the medium using 500-ml filter cups. Mix and divide the solution into 5-ml aliquots. Rspo1-conditioned medium can be stored at -20 °C for up to 6 months. (vi) Check the Rspo1 activity of each batch of conditioned medium by TOP/FOP assay 39 . TOP/FOP assay results should be at least five-to ten-fold higher in the presence of Rspo1 + wnt3a as compared with Wnt3a only. The reference for this test can be found in de Lau et al. 40 . 15 ]-gastrin I, 50 ng/ml recombinant human EGF, 25 ng/ml recombinant human HGF, 0.5 µM A83-01, 10 µM DAPT, 3 µM dexamethasone, 25 ng/ml BMP7 and 100 ng/ml recombinant human FGF19. Store the medium at 4 °C for up to 2 weeks. Mouse liver transduction medium The mouse liver transduction medium is mouse liver isolation medium supplemented with 8 µg/ml polybrene and 10 µM ROCK inhibitor (Y-27632). Store it at 4 °C for up to 2 weeks. Human liver transduction medium The human liver transduction medium is human liver isolation medium supplemented with 8 µg/ml polybrene. Store the medium at 4 °C for up to 2 weeks. proceDure culture of mouse and human liver and pancreas organoids: isolation of duct cells 1| Choose from the following options, depending on the tissue to process. Mouse liver, mouse pancreas and human pancreas are processed using option A; for human liver, follow option B.
(a) Mouse liver, mouse pancreas and human pancreas dissociation • tIMInG 4 h (i) Tissue collection.
For mouse tissue collection, euthanize the mice using an appropriate ethically approved method, and then remove the liver or pancreas as an entire organ by standard surgical procedures. For human tissue collection, after surgical excision keep the tissue cold at 4 °C in basal medium until ready for processing.  crItIcal step The common methods of mouse euthanasia do not adversely affect organoid isolation or culture.  pause poInt Mouse and human tissue can be stored in basal medium at 4 °C for up to 48 h. (ii) Transfer the tissue to the biological safety cabinet, and place it in a 100-mm Petri dish. Prewarm the digestion solution to 37 °C. (iii) Mince the tissue into pieces of roughly 0.5 mm 3 using fine scissors. Transfer minced tissue to a 15-ml centrifuge tube and add ~10 ml of ice-cold wash medium. Pipette the sample up and down with a 10-ml pipette to remove red blood cells and fat (which will float to the top of the solution). (iv) Allow tissue pieces to settle, and discard ~7.5 ml of the supernatant, including any floating pieces of fat. Repeat this wash step once. (v) Remove any remaining wash medium, and add ~10 ml of the digestion solution prewarmed to 37 °C. Incubate the digestion mixture on a shaker at 37 °C for 45 min.  crItIcal step Care should be taken to allocate the correct amounts of collagenase and dispase to the digestion solution, as inaccuracies will have a large impact on the success of duct isolation. (vi) Pipette the digestion solution up and down with a 10-ml pipette, and check an aliquot of the solution for the presence of clean duct structures using a bright-field microscope (for examples, see Fig. 2a ,b, day 0 duct isolation panels).
If none are present, return the solution to the shaker at 37 °C. Perform this check every 20-30 min.  crItIcal step Generally a large proportion of ducts will appear once no more tissue is seen by the naked eye, which will require ~2 h total incubation. (vii) When the ductal structures appear, transfer the supernatant to a fresh 15-ml centrifuge tube, add ice-cold wash medium to increase the volume to 15 ml and pellet the material at 100-300g for 5 min at 8 °C. Discard the supernatant and add cold wash medium to a volume of 15 ml; repeat the pelleting procedure again to wash out any remaining digestion solution. Step 1A(viii) in 5 ml of cold wash medium and transfer the solution to a sterile 100-mm Petri dish. Using a bright-field microscope, identify and collect ducts using a 200-µl pipette, and transfer the material to a 15-ml centrifuge tube.  crItIcal step The goal is not to achieve a pure duct culture but rather to enrich the number of ducts versus any contaminating structures/cells. ? trouBlesHootInG (x) After the collection of ducts, add 10 ml of basal medium to the 15-ml centrifuge tube, and pellet the material by centrifuging at 100-200g for 5 min at 8 °C. Remove and discard the supernatant before washing the pellet again with 10 ml of basal medium, and pellet the material again by centrifuging at 100-200g for 5 min at 8 °C. The pellet now contains isolated duct fragments that can be directly cultured (see Fig. 2 
for example). (xi) Proceed to Step 2. (B) Human liver dissociation • tIMInG 2 h
(i) After surgical excision, the tissue should be kept cold (4 °C) in basal medium until processing.  pause poInt Tissue can be stored in basal medium at 4 °C for up to 48 h. (ii) Under aseptic conditions, place the tissue into a 100-mm Petri dish and mince it into pieces of roughly 0.5-1 mm 3 using fine scissors. (iii) Transfer the minced tissue to a 15-ml centrifuge tube and add ~10 ml of ice-cold wash medium. Gently pipette up and down with a 10-ml pipette to wash the liver pieces. Allow tissue pieces to settle, and discard ~7. (viii) Pellet the material by centrifuging at 300g for 5 min at 8 °C. Remove and discard the supernatant and wash the pellet again twice with wash medium and once with 10 ml of basal medium for the final wash, each time pelleting the material by centrifuging at 300g for 5 min at 8 °C.
? trouBlesHootInG (ix) If you wish to enrich for ductal cells before the growth of organoids, sort the cells as described in Box 2 before proceeding to Step 2. If cell sorting is not required, proceed to Step 2.
seeding of duct cells • tIMInG 30 min  crItIcal Prewarm tissue culture plates at 37 °C for 1 h to overnight. For mouse cells, adherent plates can be used. For human cells, suspension plates are required to avoid cell attachment to the plate. 2| Remove the supernatant and resuspend the desired number of cells or duct structures (1,000 cells or 50 duct structures per well of a 24-well plate) in an appropriate basement matrix for seeding (i.e., Matrigel for mouse material and BME2 for human material). Use a volume of 50 µl per 24-well plate and 25 µl per 48-well plate.  crItIcal step Basement matrix (BME2 and Matrigel) requires thawing on ice at 4 °C overnight. Basement matrix will solidify at room temperature (25 °C), so it is important to work quickly and to keep the basement matrix cold throughout the process.
3|
Seed the material by adding a droplet of basement matrix to the center of each well, preventing the drop from touching the edges, as this will cause the cells to attach to the plate. Incubate the cells for 5-10 min at 37 °C or until the basement matrix is solidified.
4|
Overlay the droplet with isolation medium (500 µl per well for a 24-well plate and 250 µl per well for a 48-well plate) according to the corresponding tissue, as specified in the Reagent Setup and supplementary table 1.
5|
Incubate the material under standard tissue culture conditions (37 °C, 5% CO 2 ).  crItIcal step The interval between passages may differ slightly, depending on the initial density of organoids seeded after isolation. Prevent organoids from overgrowth (i.e., the medium turning yellow). Similarly, do not passage the organoids too soon. The general split ratio for a confluent well is 1:4-1:6.
6|
8|
Disrupt the basement matrix containing the organoids (drops in the center of the well) by scraping and pipetting up and down using 500-1,000 µl of basal medium and a 1,000-µl pipette. Transfer the organoid suspension to a 15-ml centrifuge tube, add cold basal medium to the top (~13-14 ml) and pipette up and down three to five times to remove the basement matrix.  crItIcal step Do not pool more than three wells (24-well plates) or six wells (48-well plates) together, so the basement matrix can be properly washed from the organoids.
9|
Centrifuge the tube at 100-200g for 5 min at 8 °C. Aspirate the supernatant, leaving ~2 ml of it in the tube.
Resuspend the organoids in this remaining medium.
10|
Hold a glass Pasteur pipette in a flame to narrow its aperture (by ~1/2). Using this narrowed Pasteur pipette, pipette the remaining 2 ml of supernatant up and down five to ten times in order to break the organoids.  crItIcal step Do not dissociate the organoids into single cells (Fig. 2) . If a Pasteur pipette cannot be narrowed, use 200-µl filter tips and pipette up and down until organoids are completely disrupted into fragments. Fig. 2a, liver; Fig. 2b , pancreas). 1-2 d after seeding, the duct structures or sorted cells start proliferating to generate a cyst-like structure that, in ~1 week (duct structures) or 2 weeks (sorted cells), can be mechanically dissociated and split in a 1:4-1:6 ratio for further expansion ( Fig. 2a, . 2b, pancreas) . Typically, liver and pancreas organoids are formed by a single-layer epithelium of cuboidal cells expressing ductal markers (e.g., Krt19) surrounding a central lumen. Liver organoids also exhibit some areas of pseudostratified epithelium (Fig. 3b) that resemble a liver bud structure and express low levels of the hepatocyte marker HNF4α 8 . By culturing in hepatocyte differentiation medium, the cuboidal single-layer ductal epithelium becomes a stratified polygonal epithelium formed by albumin-positive (ALB + ) and HNF4α-positive cells that fill the original lumen (Fig. 3c) . Generally, as determined by FACS or immunohistochemistry analysis, ~40% (mouse) or ~60% (human) of cells differentiate into ALB + , HNF4α + cells at days 11-14 after initiation of differentiation. Some of the cells (~1%) become bi-nucleated, which is a hallmark of mature hepatocytes. After long-term exponential expansion, the cultures remain genetically stable with virtually no accumulation of base substitutions, as determined by whole-genome sequencing analysis 9 . After expansion, characterization of the cultures can be performed using standard RNA, protein or DNA techniques (Fig. 1) similar to those used for a standard cell line.
For genetic manipulation, organoid cultures can be transiently transfected or virally transduced using the protocols described above (Fig. 4) . To achieve high levels of transfection (~10%) or transduction (~50%) efficiency, ensure that the organoids have reached their maximum size but have a minimum amount of dead cells accumulated in their lumens before genetic manipulation (see representative Fig. 5a ). Then, when preparing single cells, it is important to balance the number of single cells, larger fragments and viability of the fragments or single cells. Incubating for too long in TrypLE reduces the recovery of single cells; therefore, allowing some larger fragments will increase the overall viability (see representative Fig. 5b) . After centrifugation and incubation, very small cystic or round structures may appear. This confirms that the TrypLE treatment was adequate and that ~10-30 organoids per well should be expected to grow out over the following days. In cases in which a plasmid expressing a fluorescent protein has been used, we observed that fluorescence was visible after 36-48 h (Fig. 5c) , peaking at 48 h after transfection and decreasing after 96 h. When sorting for GFP signal was used for selection, antibiotic selection was avoided. Alternatively, when GFP selection is not available, an appropriate antibiotic selection is required. The timing of the antibiotic selection depends on the antibiotic used. When using puromycin as the selection agent, death of nontransfected/noninfected organoids was observed as soon as 4-5 d after transfection/transduction. Alternatively, when hygromycin was used, the selection process was slower and took up to 8 d. Whenever possible, transduction efficiency should be confirmed by the detection of a reporter (e.g., dsRed expression if using Addgene 32702, 32703 or 32704 retroviral vectors). Alternatively, when no reporter marker is available, a transduction control (usually a constitutive GFP-expressing virus) can be used to determine the transduction efficiency (Fig. 5d) . 
